Tikun Olam Cannbit Pharmaceuticals Ltd. Logo

Tikun Olam Cannbit Pharmaceuticals Ltd.

A vertically integrated pharma company developing research-backed, EU-GMP medical cannabis products.

TKUN | TA

Overview

Corporate Details

ISIN(s):
IL0010843675
LEI:
Country:
Israel
Address:
Ha'arbaa Street 21, 6473921 Tel Aviv-Yafo
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Tikun Olam Cannbit Pharmaceuticals Ltd. is a pioneering pharmaceutical company specializing in medical cannabis. The company operates a vertically integrated model, managing the entire value chain from genetics and cultivation to EU-GMP certified manufacturing and distribution. It focuses on developing stable, high-yielding proprietary strains with precise cannabinoid profiles to create standardized, accurately dosed products. A core differentiator is its commitment to research and development, substantiated by over 35 clinical studies and numerous scientific publications that validate the efficacy of cannabis for various medical conditions. The company also provides dedicated clinical nursing support to tens of thousands of patients, guiding their treatment and documenting outcomes.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2023-04-24 14:21
Regulatory News Service
Rights Offering and Identifying Details for New Security: TIKUN OLAM R5
Hebrew (modern) 182.1 KB
2022-08-17 17:30
Regulatory News Service
Opening of Trading On August 18 2022-TIKUN OL CN W3
Hebrew (modern) 107.6 KB
2022-07-26 15:47
Regulatory News Service
Rights Offering and Identifying Details for New Securities-Correction
Hebrew (modern) 185.9 KB
2022-07-26 15:04
Regulatory News Service
Rights Offering and Identifying Details for New Securities-TIKUN OL CAN R4, TIK…
Hebrew (modern) 314.1 KB
2021-05-30 18:08
Regulatory News Service
Tikun Olam-Cannbit – Rights Offering and Identifying Details for New Security
Hebrew (modern) 430.0 KB
2020-10-14 14:50
Regulatory News Service
Tikun Olam Canb – Rights Offering and Identifying Details for New Security
Hebrew (modern) 431.2 KB

Automate Your Workflow. Get a real-time feed of all Tikun Olam Cannbit Pharmaceuticals Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Tikun Olam Cannbit Pharmaceuticals Ltd.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Tikun Olam Cannbit Pharmaceuticals Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
SEOUL PHARMA CO.,LTD Logo
Develops pharmaceuticals with innovative Orally Disintegrating Film (ODF) tech for global markets.
South Korea 018680
SEYİTLER KİMYA SANAYİ A.Ş. Logo
Manufacturer of medical tapes, wound dressings, and first aid plasters for the healthcare industry.
Türkiye SEYKM
Shaperon Inc. Logo
Develops inflammasome inhibitors & nanobodies for inflammatory diseases and cancer.
South Korea 378800
Shedir Pharma Group Logo
Develops and sells pharmaceutical, nutraceutical, and dermo-cosmetic products in Italy & Spain.
Italy SHE
SHIELD THERAPEUTICS PLC Logo
Commercializing a novel oral therapy for adults with iron deficiency.
United Kingdom STX
SHINPOONG PHARMACEUTICAL CO.,LTD Logo
R&D-driven pharma firm making APIs, finished drugs, and medical products for global markets.
South Korea 019170
Shionogi & Co.,Ltd. Logo
A research-driven pharmaceutical firm creating drugs, diagnostics, and devices for global health.
Japan 4507
Siegfried Holding AG Logo
Global CDMO providing development and manufacturing of APIs and finished drugs for the pharma industry.
Switzerland SFZN
Develops oncolytic viruses and immunotherapeutics to destroy difficult-to-treat cancer cells.
South Korea 215600
SK biopharmaceuticals Co., Ltd. Logo
Develops and commercializes CNS and oncology therapies for global markets, focusing on the U.S.
South Korea 326030

Talk to a Data Expert

Have a question? We'll get back to you promptly.